OBJECTIVELY
ASSESS MILD TBI

AT THE POINT OF CARE

The i-STAT TBI cartridge* is the first point-of-care venous whole blood test for mild TBI that measures brain-specific biomarkers and delivers objective data in 15 minutes.1

*Available only on the i-STAT Alinity instrument | TBI=traumatic brain injury
background image background image background image

OBJECTIVELY ASSESS
MILD TBI

AT THE POINT OF CARE

The i-STAT TBI cartridge* is the first point-of-care venous whole blood test for mild TBI that measures brain-specific biomarkers and delivers objective data in 15 minutes.1

*Available only on the i-STAT Alinity instrument | TBI=traumatic brain injury

INNOVATIONS IN PATIENT CARE

What impact will the i-STAT TBI cartridge have on your patients and care team? Contact us and explore our innovative, point-of-care products that deliver lab-quality results in minutes.

background image background image

INNOVATIONS IN PATIENT CARE

What impact will the i-STAT TBI cartridge have on your patients
and care team?

ADDITIONAL RESOURCES
Biomarkers in Assessing mTBI

This white paper explains more about the role biomarkers play in the assessment of mild traumatic brain injury.

biomarker

Explore the science behind the evaluation of traumatic brain injury through this web site's articles, videos and related content.

Biomarkers in Assessing mTBI

Discover more on the role of biomarkers (GFAP and UCH-L1) in assessing mild traumatic brain injury (mTBI).

REFERENCES

  1. i-STAT TBI cartridge. Instructions for use. Abbott Point of Care Inc. Abbott Park, IL; 2024.
  2. Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 2016;12(10):563-574.
  3. Chodobski A, Zink BJ, Symydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011;2(4):492-516.
  4. Metting Z, Wilczak N, Rodiger LA, et al. GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology. 2012;78(18):1428-1433.
  5. Papa L, Lewis LM, Falk JL, et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med. 2012;59(6):471-483.
  6. Jones A, Jarvis P. Review of the potential use of blood neuro-biomarkers in the diagnosis of mild traumatic brain injury. Clin Exp Emerg Med. 2017;4(3):121-127.
  7. Schulte S, Podlog LW, Hamson-Utley JJ, et al. A systematic review of the biomarker S100B: implications for sport-related concussion management. J Athl Train. 2014;49(6):830-850.
  8. Steiner J, Bernstein H-G, Bielau H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 2007;8:2.
  9. Pelinka LE, Kroepfl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma. 2004;57(5):1006-1012.
  10. Diaz-Arrastia R, Wang KKW, Papa L, et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma. 2014;31(1):19-25.
  11. Papa L, Lewis LM, Silvestri S, et al. Serum levels of ubiquitin C-terminal hydrolase (UCH-L1) distinguish mild traumatic brain injury (TBI) from trauma controls and are elevated in mild and moderate TBI patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg. 2012;72(5):1335-1344.
  12. Papa L, Brophy GM, Welch RD, et al. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 2016;73(5):551-560.